Skip to content
Disclosery

Ally Bridge Group (NY) LLC

Follow

13F filer, CIK 1822947, NEW YORK, NY

Ally Bridge Group (NY) LLC reported $113,071,435 across 25 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 64.83% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-352338

Period
2026-06-30
Reported value
$113M
Holdings
25
Top 10 weight
64.83%
New
12
Sold out
14

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TRAXnew+284,287$5.72M
AXSMnew+16,493$4.04M
ASMBnew+140,000$3.85M
CLYMnew+249,172$3.25M
KURAnew+290,000$3.18M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PRAXexited-32,810-$10.6M
SLNOexited-200,000-$6.7M
OVIDreduced-2,193,898-$5.9M
CMPSexited-1,045,000-$5.78M
TARSexited-80,859-$5.67M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-352338, largest first. % of portfolio is the value over $77,597,935, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,655,500 shares; 2026Q1: 1,655,500 shares; 2026Q2: 2,175,802 shares 2,175,802$12.1M15.56%+520,302Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 249,339 shares; 2026Q1: 414,219 shares; 2026Q2: 620,319 shares 620,319$8.16M10.52%+206,100Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 284,287 shares 284,287$5.72M7.37%newTimeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 66,661 shares; 2025Q1: 72,113 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 16,493 shares 16,493$4.04M5.2%newTimeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 140,000 shares 140,000$3.85M4.96%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 817,939 shares; 2025Q1: 817,939 shares; 2025Q2: 817,939 shares; 2025Q3: 817,939 shares; 2025Q4: 817,939 shares; 2026Q1: 817,939 shares; 2026Q2: 817,939 shares 817,939$3.75M4.83%0Timeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 187,695 shares; 2024Q4: 83,176 shares; 2025Q1: 102,650 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 195,000 shares; 2026Q1: 161,000 shares; 2026Q2: 83,300 shares 83,300$3.38M4.36%-77,700Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,229,292 shares; 2024Q4: 760,225 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 249,172 shares 249,172$3.25M4.19%newTimeline
KURAKURA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 294,081 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 290,000 shares 290,000$3.18M4.1%newTimeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 900,000 shares; 2026Q2: 775,000 shares 775,000$2.91M3.75%-125,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 178,100 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares 150,000$2.77M3.57%newTimeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,229,000 shares 1,229,000$2.57M3.31%newTimeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 724,000 shares; 2025Q3: 549,182 shares; 2025Q4: 413,625 shares; 2026Q1: 766,974 shares; 2026Q2: 255,959 shares 255,959$2.56M3.3%-511,015Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 526,315 shares; 2026Q2: 526,315 shares 526,315$2.55M3.28%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 202,124 shares; 2026Q2: 69,183 shares 69,183$2.55M3.28%-132,941Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 341,739 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 926,557 shares; 2026Q2: 743,958 shares 743,958$2.54M3.27%-182,599Timeline
IDYAIDEAYA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 67,500 shares 67,500$2.52M3.24%newTimeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 745,300 shares; 2026Q2: 634,800 shares 634,800$2.4M3.09%-110,500Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 418,416 shares; 2024Q4: 445,259 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 166,959 shares; 2026Q2: 76,459 shares 76,459$2.15M2.77%-90,500Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,785,000 shares; 2026Q1: 2,818,459 shares; 2026Q2: 624,561 shares 624,561$1.68M2.17%-2,193,898Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 915,000 shares; 2025Q4: 397,895 shares; 2026Q1: 660,375 shares; 2026Q2: 252,175 shares 252,175$1.67M2.15%-408,200Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 390,147 shares 390,147$683K0.88%newTimeline
TRAWTRAWS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 786,236 shares 786,236$663K0.85%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
DFTXDEFINIUM THERAPEUTICS INC COM SHScall400,000$18.8Mnew
ABVXABIVAX SA SPONSORED ADScall125,000$16.7Mnew

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PRAXPRAXIS PRECISION MEDICINES I32,810$10.6Mshares
SLNOSOLENO THERAPEUTICS INC200,000$6.7Mshares
SLNOSOLENO THERAPEUTICS INC200,000$6.7Mput
CMPSCOMPASS PATHWAYS PLC1,045,000$5.78Mshares
TARSTARSUS PHARMACEUTICALS INC80,859$5.67Mshares
CMPXCOMPASS THERAPEUTICS INC1,000,000$5.29Mcall
QUREUNIQURE NV300,000$4.91Mcall
ABVXABIVAX SA33,712$3.75Mshares
CAPRCAPRICOR THERAPEUTICS INC113,899$3.46Mshares
MAZEMAZE THERAPEUTICS INC100,000$2.98Mcall
IKTINHIBIKASE THERAPEUTICS INC1,325,000$2.23Mshares
REPLREPLIMUNE GROUP INC246,900$1.89Mcall
RLMDRELMADA THERAPEUTICS INC210,525$1.47Mshares
KPTIKARYOPHARM THERAPEUTICS INC250,000$1.39Mcall

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-352338 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-352338 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001193125-26-227559 Quarter ended 2026-03-312026-05-18acceptance time not in the bulk data set
13F-HR 0001193125-26-055035 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001193125-25-283054 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0000950123-25-008419 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000950123-25-005586 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0000950123-25-002405 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0000950123-24-011470 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0000950123-24-008408 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0000950123-24-005227 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0000950123-24-002153 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0000950123-23-010736 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0000950123-23-008083 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0000950123-23-004992 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0000950123-23-002336 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0000950123-22-011716 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0000950123-22-009121 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0000950123-22-005946 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0000950123-22-002404 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0000950123-21-015123 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0000950123-21-011101 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0000950123-21-006746 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0000950123-21-002363 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set